{"name":"CrystalGenomics, Inc.","slug":"crystalgenomics-inc","ticker":"","exchange":"","domain":"crystalgenomics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CG100649","genericName":"CG100649","slug":"cg100649","indication":"Atopic dermatitis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CG400549","genericName":"CG400549","slug":"cg400549","indication":"Multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"CG100649","genericName":"CG100649","slug":"cg100649","phase":"phase_3","mechanism":"CG100649 is a selective inhibitor of cathepsin S that reduces inflammatory responses by modulating immune cell activation and antigen presentation.","indications":["Atopic dermatitis","Other autoimmune and inflammatory conditions"],"catalyst":""},{"name":"CG400549","genericName":"CG400549","slug":"cg400549","phase":"phase_2","mechanism":"CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses.","indications":["Multiple myeloma","Peripheral T-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNd0xfQ0dxa0VhdGNvZ1pjd21Td2ZuSS0zbjNqMWtDU1dmNU5CLV8xUkFsdVR5TjJFQTBrdVdudjg0WGN4QUJrdmNJYnZ2TEVTVnFFTXFxQU5STWdKc21XbkNMM0JuWXpqUTNFVklKcUpzTk4yV21DS2lPR1Yxd0dERWUtc1ExOTRfcF84MWI0MFNiLS1ZclZKM0FBS3dUbndRWU4wLUhHM2xndFRFcHVKak52cVUxWS1MM0NlUUQ5NkF2UEJKY1ZtMTRZbkkxenFYVGstVUw3TnNvUHlaQkNpMlAxeXZwdl8wdkFvQVBmbEV2ZXk5YlYzSkV6dkJ2bm9rb2lGWmVJcEw2czgyZEJscFB2cUdrdlRXcllUbnZVVVNxSUx0M0x6YlA0Z0ZNZ29VTVpXbE9Tdw?oc=5","date":"2024-01-08","type":"trial","source":"GlobeNewswire","summary":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9JUFhDZW4wYlZjWTl6M2tBVVhjNVNmQVVUNnVQWmNOVU9CY28wT0ktTUx1UUZqTW1lSF9nTWc5YnkzQTVMTDRXR1NHU2dRZUJCcFFGXzlXal84ZHMxVVpUNXBCeGhjVExvYUtnaFdR0gFyQVVfeXFMTXNYdm96cFlBRWEwaW8xZ2puUUZvUHdDVXpGQ09iYWhZMnNaTVRteDRNWm5IbXpjMFZaaUZyTFhFc1NBXzc0Sk9rRVZUN2NWMFk4UUNDZklrXzY0bi1sbGFHNDJCRzJudVpJWlJNZERxcE5R?oc=5","date":"2023-08-04","type":"pipeline","source":"koreabiomed.com","summary":"Crystal Genomics restarts as CG Invites - koreabiomed.com","headline":"Crystal Genomics restarts as CG Invites","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBqT2lDRUxQcFROVndJUXRTbENLUmR3eEZEZ3BFYjlCd1JCdEJLeW1kM2FUTnlHZGhCbWpmNGpsMkpIdWE5elhfWmVPclVXY0l4WW14N0tlUXJqOUt1QlhqdVIyOGZRQmw5WmNrVGZB?oc=5","date":"2023-06-08","type":"pipeline","source":"KED Global","summary":"CrystalGenomics to supply anti-osteoarthritis drug to Russia for $2 mn - KED Global","headline":"CrystalGenomics to supply anti-osteoarthritis drug to Russia for $2 mn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE12NnQwd3hhYjhIVUhiMUwtVGx3ZHVnM1NKZHZGM0VkRTZVTEZ1ampDbXo4UWczdjF3VjBoUXpMR25FQXJ0RkNhbDQzY0hkOHVhTGRucVBqZ2tVNnMxdjYwNy1ETURGMzYwWERiWFJ3?oc=5","date":"2023-05-23","type":"pipeline","source":"KED Global","summary":"CrystalGenomics to sell largest 20% stake to Invites Healthcare for $44 mn - KED Global","headline":"CrystalGenomics to sell largest 20% stake to Invites Healthcare for $44 mn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE51cEVzSDQ5UE1UQ2NjWWhibExhTlQ0Zl9UX2w1bndmLXFWMkRGenJlU1hyYnhSVy1TVGh6T3NONWo4bTgyQ3FMQ2x1S2RXUTFvWHlsMzBB?oc=5","date":"2020-10-08","type":"pipeline","source":"The Korea Herald","summary":"CrystalGenomics appoint Gavin Choy as CEO of CG Pharmaceuticals - The Korea Herald","headline":"CrystalGenomics appoint Gavin Choy as CEO of CG Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPN0VKUVpMbHhyaEV1U0xFS3FpS2YzaE1sb195anRqYU5QX3V5ZEZ0NW8tczZhNnV4aXZISmVtRHlHRm5UODZlUmducXpscHZfcmJBQnAzZThKZHB1Y0FMQnNrZm5DaXpFUEt1SW1Zc1poTzQ4THRqZzVTdUdYS28zZ1d4akY0ejhsUVQzUUEya3JEaUd3ZzdpNDRqYXRsNm92OGR6QVFmdy10YkN4ZlBrQzJMRkQ1QmlLUGJqVFc0OWpOaTdDZjRncHNOZTVjLVZnd2RsZlVibjhHSkdZQUc3aW9MT2dFUXhabEZwamJLdlNaN2I2MHc?oc=5","date":"2018-06-14","type":"deal","source":"GlobeNewswire","summary":"Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China - GlobeNewswire","headline":"Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}